The novel agent, DISC-0974, shows high selectivity for HFE2, this crucial regulator playing during mammalian morphogenesis. Initial studies suggest that inhibiting RGMC/HFE2 activity with this therapeutic results in https://www.targetmol.com/compound/disc_0974